This week, the FDA granted priority review status to J&J’s JNJ application seeking approval of key pipeline candidate ...
On Tuesday, January 7, the FDA announced it would now be requiring GSK and Pfizer’s RSV vaccines to hold warnings of a risk ...
As for GBS itself, this neurological ailment can be severe, attacking nerves and warranting hospitalisation for weeks or ...
Tens of millions of pounds in investment is being provided by the group of firms which includes AstraZenecaa and Pfizer ...
Drugmakers have started 2025, implementing price hikes for 583 products within the first two days of the new year alone, ...
3hon MSN
Alzhemier’s disease could be diagnosed up to a decade earlier after the world’s biggest study of proteins is completed. The ...
Royalty Pharma plc to become an integrated company by acquiring its external manager, RP Management, LLCSignificant annual cash savings of ...
Portfolio Receipts expected to be approximately $2,800 million, at the upper end of guidance rangeExciting development-stage pipeline with ...
A world leading UK Biobank study of half a million Brits could unlock the mysteries of ‘proteomics’ to prevent and cure ...
Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2025 of $0.22 per Class A ordinary share, reflecting a 5% increase in the ...
Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback